Actively Recruiting
Phase 2 Evaluation of ADX-038 for Treatment of Complement-Mediated Kidney Diseases Including IgAN and C3G
Led by ADARx Pharmaceuticals, Inc. · Updated on 2026-10-20
45
Participants Needed
38
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ADX-038, a drug delivered as siRNA duplex oligonucleotides, in adults with complement-mediated kidney diseases including IgA Nephropathy IgAN, C3 Glomerulopathy C3G, and Immune Complex-Mediated Membranoproliferative Glomerulonephritis IC-MPGN. This Phase 2 study aims to assess the safety, effectiveness, pharmacokinetics, and pharmacodynamics of ADX-038 in these patients. The study is sponsored by ADARx Pharmaceuticals, Inc. Participants receive one of several doses of ADX-038, categorized as Dose Level 1 or Dose Level 2, targeting different complement-mediated kidney conditions. The study follows a parallel design without randomization or masking. Treatment is administered over a period of up to 36 months, allowing researchers to observe long-term effects and safety. During the trial, participants will be monitored regularly to evaluate safety and tolerability, which is the primary outcome measure tracked for up to 36 months. Clinical evaluations, laboratory tests, and pharmacokinetic and pharmacodynamic assessments will be conducted to gather comprehensive data. Participants are expected to continue supportive care treatments, including ACE inhibitors or ARBs if applicable, and will receive necessary vaccinations as part of the study protocol.
CONDITIONS
Brief Title
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Research Team
T
Tracy Nguyen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here